Urokinase-type plasminogen activator receptor (uPAR), commonly upregulated on senescent cells, has been exploited for uPAR-specific CAR-T cell therapies to selectively eliminate senescent cells in vitro and in vivo, leading to improved outcomes in mouse models of lung cancer and liver fibrosis (213). Here, PLAUR is linked to Hepatic fibrosis.